Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer

Anticancer Research

Volumn 16, Issue 4 B, 1996, Pages 2205-2207

  Van Poppel, Hein ^a   Billen, Jaak ^a   Goethuys, Hans ^a   Elgamal, Aziz A ^a   Gerits, Mathieu ^a   Mortelmans, Luc ^a   Blanckaert, Norbert ^a   Baert, Luc ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Bladder cancer; TPA; Tumor markers

Indexed keywords

TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA;

HUMANS; PEPTIDES; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0029840720     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Björklund B, Björklund V: Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique: presence of an insoluble, heat labile tumor antigen. Int Arch Allergy 10: 153-184, 1957.
2. Maulard C, Toubert ME, Chretien Y, Delanian S, Defour B, Housset M: Serum tissue polypeptide antigen (S-TPA) in bladder cancer as a tumor marker. A prospective study. Cancer 73: 394-398, 1994.
3. Carbin BE, Collins VP, Ekman P: Tissue polypeptide antigen (TPA). some cytokeratins and epithelial membrane antigen (EMA) in normal, inflamed and malignant urothelium. Urol Res 15: 191-194, 1987.
4. Mellerick DM, Osborn M, Weber K: On the nature of serological tissue polypeptide antigen (TPA); monoclonal keratin 8, 18, and 19 antibodies react differently with TPA prepared from human cultured carcinoma cells and TPA in human serum. Oncogene 5; 1007-1017, 1990.
5. Fischer LN, Carbin BE, Baecklander M: TPA in urine from patients with bladder cancer and controls. J Tum Marker Oncol 8: 64-68, 1993.
6. Adolphs HD, Oehr P: Significance of plasma tissue polypeptide antigen determination for diagnosis and follow-up of urothelial bladder cancer. Urol Res 12: 125-128, 1984.
7. Khanna OP, Wer B: Tissue polypeptide antigen (TPA) as a predictor for genito-urinarycancers and their metastases. Urology 30: 106-110, 1987.
8. Kumar S, Costello CB, Glashan RW, Björklund RB: The clinical significance of tissue polypeptide antigen (TPA) in the urine of bladder cancer patients. Br J Urol 53: 578-581, 1481.
9. Carbin BE, Ekman P, Eneroth P, Nilsson B: Urine-TPA (tissue polypeptide antigen), flowcytometry and cytology as markers for tumor invasiveness in urinary bladder carcinoma. Urol Res 17: 269-272, 1489.
10. Ruther U, Luthgens M, Bauerle K, Rassweiler J, Bub P, Eisenberger F, Jipp P, Kruse-Jarres J-D: Surveillance and M-VEC therapy monitoring of patients with advanced carcinoma of the urinary tract by TPA. J Tumor Marker Oncol 4: 303-321, 1989.
11. Van der Gaast A, Kirkels WJ, Blijenherg BG, Splinter TAW: Evaluation of tissue polypeptide antigen serum levels for monitoring disease activity during chemotherapy in patients with transitional carcinoma of the urinary tract. J Cancer Res Clin Oncol 118: 626-628, 1992.